$CYRX
Cryoport, Inc. Stock $cyrx

$cyrx Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000114420416134450 Filed on November 14, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2016 Q1
Revenue	$2.229M	$1.977M	$0.00
YoY Change	52.78%	37.58%	-100.0%
Cost Of Revenue	$1.290M	$1.180M	$973.7K
YoY Change	20.56%	17.92%	17.32%
Gross Profit	$941.0K	$797.0K	$0.00
YoY Change	145.05%	82.8%	-100.0%
Gross Profit Margin	42.22%	40.31%
Selling, General & Admin	$2.840M	$2.743M	$3.060M
YoY Change	0.16%	26.99%	54.55%
% of Gross Profit	301.81%	344.16%
Research & Development	$100.0K	$214.7K	$144.5K
YoY Change	-56.1%	114.05%	60.53%
% of Gross Profit	10.63%	26.94%
Depreciation & Amortization	$100.0K	$100.0K	$72.90K
YoY Change	25.0%	150.0%	82.26%
% of Gross Profit	10.63%	12.55%
Operating Expenses	$2.940M	$2.958M	$144.5K
YoY Change	-4.02%	30.98%	-92.99%
Operating Profit	-$2.002M	-$2.161M	$0.00
YoY Change	-25.27%	18.62%	-100.0%
Interest Expense	-$20.00K	$19.31K	-$80.00K
YoY Change	-125.02%	-96.79%	-66.67%
% of Operating Profit
Other Income/Expense, Net	-$2.260M	$0.00	$0.00
YoY Change	167680.25%	-100.0%
Pretax Income	-$4.280M	-$2.182M	-$2.710M
YoY Change	55.06%	-10.05%	39.69%
Income Tax	$0.00	$2.878K	$0.00
% Of Pretax Income
Net Earnings	-$4.284M	-$2.184M	$0.00
YoY Change	55.19%	-9.96%	-100.0%
Net Earnings / Revenue	-192.19%	-110.47%
Basic Earnings Per Share
Diluted Earnings Per Share	-$254.0K	-$144.2K	-$256.1K
COMMON SHARES
Basic Shares Outstanding	17.60M shares	15.12M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.500M	$2.600M	$2.800M
YoY Change	-13.46%	-63.38%	100.0%
Cash & Equivalents	$4.525M	$2.558M	$2.793M
Short-Term Investments
Other Short-Term Assets	$300.0K	$600.0K	$200.0K
YoY Change	3.82%	200.0%	105.47%
Inventory	$89.50K	$82.19K	$69.80K
Prepaid Expenses
Receivables	$1.195M	$1.000M	$1.021M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.096M	$4.247M	$4.132M
YoY Change	-1.77%	-46.91%	91.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.647M	$1.373M	$1.320M
YoY Change	88.1%	71.65%	328.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$400.0K	$400.0K	$400.0K
YoY Change	0.0%
Total Long-Term Assets	$2.016M	$1.753M	$1.692M
YoY Change	60.91%	94.75%	280.38%
TOTAL ASSETS
Total Short-Term Assets	$6.096M	$4.247M	$4.132M
Total Long-Term Assets	$2.016M	$1.753M	$1.692M
Total Assets	$8.112M	$6.000M	$5.824M
YoY Change	8.76%	-32.58%	123.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.200M	$1.200M	$1.300M
YoY Change	9.09%	33.33%	62.5%
Accrued Expenses	$400.0K	$400.0K	$500.0K
YoY Change	0.0%	0.0%	-28.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$700.0K	$700.0K	$400.0K
YoY Change	-30.0%	-30.0%
Total Short-Term Liabilities	$2.231M	$2.292M	$2.174M
YoY Change	-9.6%	4.19%	-27.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$600.0K
YoY Change
Other Long-Term Liabilities	$200.0K
YoY Change
Total Long-Term Liabilities	$200.0K	$0.00	$600.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.231M	$2.292M	$2.174M
Total Long-Term Liabilities	$200.0K	$0.00	$600.0K
Total Liabilities	$2.432M	$2.292M	$2.728M
YoY Change	-1.49%	4.19%	-9.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$123.5M	-$119.3M	-$113.1M
YoY Change			15.71%
Common Stock	$129.2M	$122.9M	$116.2M
YoY Change	13.01%		19.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.680M	$3.698M	$3.096M
YoY Change
Total Liabilities & Shareholders Equity	$8.112M	$6.000M	$5.824M
YoY Change	8.76%	-32.58%	123.42%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2016 Q1
OPERATING ACTIVITIES
Net Income	-$4.284M	-$2.184M	$0.00
YoY Change	55.19%	-9.96%	-100.0%
Depreciation, Depletion And Amortization	$100.0K	$100.0K	$72.90K
YoY Change	25.0%	150.0%	82.26%
Cash From Operating Activities	-$760.0K	-$1.530M	-$1.970M
YoY Change	-45.71%	42.99%	52.71%
INVESTING ACTIVITIES
Capital Expenditures	-$390.0K	-$80.00K	-$410.0K
YoY Change	5.41%	-65.22%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$390.0K	-$80.00K	-$410.0K
YoY Change	5.41%	-65.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$3.700M		$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.120M	-360.0K	-80.00K
YoY Change	-7900.0%	-106.03%	-104.17%
NET CHANGE
Cash From Operating Activities	-760.0K	-1.530M	-1.970M
Cash From Investing Activities	-390.0K	-80.00K	-410.0K
Cash From Financing Activities	3.120M	-360.0K	-80.00K
Net Change In Cash	1.970M	-1.970M	-2.460M
YoY Change	-208.84%	-142.18%	-490.48%
FREE CASH FLOW
Cash From Operating Activities	-$760.0K	-$1.530M	-$1.970M
Capital Expenditures	-$390.0K	-$80.00K	-$410.0K
Free Cash Flow	-$370.0K	-$1.450M	-$1.560M
YoY Change	-64.08%	72.62%	20.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	us-gaap	Liabilities Liabilities	2727853	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	12251	USD
CY2016Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	116214522	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113130846	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	3095927	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	606823	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	248729	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	69801	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	4132055	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1319741	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8581	USD
CY2016Q1	us-gaap	Deposits Assets DepositsAssets	363403	USD
CY2016Q1	us-gaap	Assets Assets	5823780	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	508754	USD
CY2016Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	392898	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1020999	USD
CY2016Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1271926	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2173578	USD
CY2016Q1	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	554275	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5823780	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2558028	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1000226	USD
CY2016Q3	us-gaap	Inventory Net InventoryNet	82191	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	4247268	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1373207	USD
CY2016Q3	us-gaap	Deposits Assets DepositsAssets	363403	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2292242	USD
	us-gaap	Operating Expenses OperatingExpenses	5718872	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3437923	USD
	us-gaap	Interest Expense InterestExpense	40547	USD
	us-gaap	Interest Expense InterestExpense	904802	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3368	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3682	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6113820	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4346407	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5362	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3320	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6119182	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4349727	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5774389	shares
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2402248	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1781880	USD
CY2016Q3	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	0	USD
CY2016Q3	us-gaap	Liabilities Liabilities	2292242	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	15128	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	122932859	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119250028	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	3697959	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	350479	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	178020	USD
	us-gaap	Operating Expenses OperatingExpenses	4362148	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4140087	USD
	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	4474348	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	447878	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6119182	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9271953	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.61
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14662626	shares
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2937402	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2430991	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1929818	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1976826	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1437028	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	1000715	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	214680	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100296	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	2957667	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	2258067	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2160832	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1821754	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	19305	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	601002	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2707	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2181590	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2425463	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2878	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-2184468	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-2425463	USD
CY2016Q3	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
CY2015Q3	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
CY2016Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2184468	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15120479	shares
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1507634	USD
CY2016Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1235353	USD
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	741377	USD
CY2016Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	966000	USD
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	cyrx	Maturity Period Of Highly Liquid Investments MaturityPeriodOfHighlyLiquidInvestments	P90D
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	22100	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	198617	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12463	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	351568	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1548993	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1118012	USD
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-16372	USD
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-32817	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	32790	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	34043	USD
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	12017	USD
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	147252	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12390	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-88156	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-140519	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-341069	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	7012	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2984293	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2942356	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	261197	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	335402	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-266197	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-335402	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	226971	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	172000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3015992	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8932281	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-234498	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	5654523	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1405186	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7059709	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3896678	USD
	cyrx	Convertible Preferred Stock Beneficial Conversion Feature And Fair Value Of Warrants Issued ConvertiblePreferredStockBeneficialConversionFeatureAndFairValueOfWarrantsIssued	0	USD
	cyrx	Convertible Preferred Stock Beneficial Conversion Feature And Fair Value Of Warrants Issued ConvertiblePreferredStockBeneficialConversionFeatureAndFairValueOfWarrantsIssued	4474348	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	358094	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	91336	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2244247	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
	cyrx	Proceeds From Rights Offering Net Of Offering Cost ProceedsFromRightsOfferingNetOfOfferingCost	-998716	USD
	cyrx	Proceeds From Rights Offering Net Of Offering Cost ProceedsFromRightsOfferingNetOfOfferingCost	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	10881	USD
	cyrx	Consulting Service Fee ConsultingServiceFee	224400	USD
	cyrx	Consulting Service Fee ConsultingServiceFee	140500	USD
CY2016Q3	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	739000	USD
CY2016Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.88
	us-gaap	Legal Fees LegalFees	5000	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	28100	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	28900	USD
CY2016Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	13000	USD
CY2016Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	6100	USD
CY2016Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13915521	shares
CY2016Q2	cyrx	Class Of Warrant Or Right Number Of Warrants Exercised ClassOfWarrantOrRightNumberOfWarrantsExercised	2020597	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12251313	shares
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	Cryoport, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001124524
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	CYRX
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17599028	shares
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	30000	USD
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15128115	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15128115	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12251313	shares
	cyrx	Debt Instrument Convertible Beneficial Conversion Feature Related Party Notes Payable DebtInstrumentConvertibleBeneficialConversionFeatureRelatedPartyNotesPayable	0	USD
	cyrx	Debt Instrument Convertible Beneficial Conversion Feature Related Party Notes Payable DebtInstrumentConvertibleBeneficialConversionFeatureRelatedPartyNotesPayable	-521056	USD
	cyrx	Proceeds From Issuance Common Stock And Warrants Public Offering ProceedsFromIssuanceCommonStockAndWarrantsPublicOffering	0	USD
	cyrx	Proceeds From Issuance Common Stock And Warrants Public Offering ProceedsFromIssuanceCommonStockAndWarrantsPublicOffering	-5938099	USD
	cyrx	Proceeds From Issuance Of Common Stock Accrued Board Of Director Compensation ProceedsFromIssuanceOfCommonStockAccruedBoardOfDirectorCompensation	0	USD
	cyrx	Proceeds From Issuance Of Common Stock Accrued Board Of Director Compensation ProceedsFromIssuanceOfCommonStockAccruedBoardOfDirectorCompensation	54813	USD
	cyrx	Noncash Or Part Noncash Acquisition Fixed Assets Acquired Accounts Payable And Other Accrued Expenses NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredAccountsPayableAndOtherAccruedExpenses	0	USD
	cyrx	Noncash Or Part Noncash Acquisition Fixed Assets Acquired Accounts Payable And Other Accrued Expenses NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredAccountsPayableAndOtherAccruedExpenses	200000	USD
	cyrx	Noncash Or Part Noncash Acquisition Reclassification Of Shipper Inventory To Fixed Assets NoncashOrPartNoncashAcquisitionReclassificationOfShipperInventoryToFixedAssets	0	USD
	cyrx	Noncash Or Part Noncash Acquisition Reclassification Of Shipper Inventory To Fixed Assets NoncashOrPartNoncashAcquisitionReclassificationOfShipperInventoryToFixedAssets	32074	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 2. Nature of the Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.34in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary Cryoport Express<sup style="font-style:normal">®</sup> Shippers, Cryoportal Logistics Management Platform, SmartPak II<sup style="font-style:normal"></sup> Condition Monitoring System and specialized cold chain logistics expertise. The Company provides leading edge end-to-end logistics solutions for temperature-sensitive life science commodities, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Leading global companies, such as FedEx, UPS and DHL have each separately selected Cryoport as the preferred cryogenic logistics provider for time- and temperature-sensitive biological material. Cryoport actively supports points-of-care, contract research organizations, central laboratories, pharmaceutical companies, contract manufacturers and university researchers.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.34in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in" align="justify"><b><i><font style="FONT-SIZE: 10pt">Going Concern</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.34in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The condensed consolidated financial statements have been prepared using the accrual method of accounting in accordance with U.S. GAAP and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. We have sustained operating losses since our inception and have used substantial amounts of working capital in our operations. At September 30, 2016, we had an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">119.3</font> million. During the six months ended September 30, 2016, we used cash in operations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.0</font> million and had a net loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.1</font> million.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We expect to continue to incur substantial additional operating losses from costs related to the commercialization of our Cryoport Express<sup style="font-style:normal">®</sup> Solutions and do not expect that revenues from operations will be sufficient to satisfy our funding requirements in the near term. We believe that our cash and cash equivalents at September 30, 2016, the net proceeds from the October 2016 Tender Offer (See Note 8) and revenues generated from our services will be sufficient to sustain our planned operations into the second quarter of calendar year 2017; however, we must obtain additional capital to fund operations thereafter and for the achievement of sustained profitable operations. These factors raise substantial doubt about our ability to continue as a going concern. We are currently working on funding alternatives in order to secure sufficient operating capital to allow us to continue to operate as a going concern.</font></div>  <font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.34in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Future capital requirements will depend upon many factors, including the success of our commercialization efforts and the level of customer adoption of our Cryoport Express<sup style="font-style:normal">®</sup> Solutions as well as our need to expand our operational infrastructure, including the additional acquisition of Cryoport Express<sup style="font-style:normal">®</sup> Shippers and other equipment in response to our client’s needs. We cannot make any assurances that the sales ramp will lead to achievement of sustained profitable operations or that any additional financing efforts will be successful.. Management’s inability to achieve significant revenue increases or to complete any future financing will adversely impact our ability to continue as a going concern.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt"> Reclassification</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">  </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Certain prior period financial statement amounts have been reclassified to conform to the current period presentation.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments and conversion features.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q3	cyrx	Consulting Service Fee ConsultingServiceFee	141700	USD
CY2015Q3	cyrx	Consulting Service Fee ConsultingServiceFee	66200	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4186999	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	103468	shares
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Fiscal Period FiscalPeriod	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Change in Fiscal Year End</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">  </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In September 2016, the Company elected to change its fiscal year end from March 31 to a new fiscal year end of December 31. As a result of the change, the Company’s quarterly reporting periods will be comprised of the three calendar months ending March 31, June 30, September 30, and December 31. Following the filing of this Quarterly Report on Form 10-Q, the Company’s next periodic report will be filed on Form 10-K for the transition period from April 1, 2016 to December 31, 2016.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name	View Source	Status
0001144204-16-134450-index-headers.html	Edgar Link	pending
0001144204-16-134450-index.html	Edgar Link	pending
0001144204-16-134450.txt	Edgar Link	pending
0001144204-16-134450-xbrl.zip	Edgar Link	pending
cyrx-20160930.xml	Edgar Link	completed
cyrx-20160930.xsd	Edgar Link	pending
cyrx-20160930_cal.xml	Edgar Link	unprocessable
cyrx-20160930_def.xml	Edgar Link	unprocessable
cyrx-20160930_lab.xml	Edgar Link	unprocessable
cyrx-20160930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pg1img1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v452252_10q.htm	Edgar Link	pending
v452252_ex31-1.htm	Edgar Link	pending
v452252_ex31-2.htm	Edgar Link	pending
v452252_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYRX
Cryoport, Inc. Stock $cyrx

2016 Q4 Form 10-Q Financial Statement

#000114420416134450 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX Cryoport, Inc. Stock $cyrx

2016 Q4 Form 10-Q Financial Statement

#000114420416134450 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX
Cryoport, Inc. Stock $cyrx